Sign In
Buy CLRB
$2.57
+0.0400 (+1.58%)
At Close: Jul 31, 2026
All You Need to Know About Cellectar Biosciences (CLRB) Rating Upgrade to Buy
01:01pm, Tuesday, 15'th Jul 2025
Cellectar Biosciences (CLRB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option
04:15pm, Wednesday, 02'nd Jul 2025
FLORHAM PARK, N.J., July 02, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the “Company”), a late-stage clinical biopharmaceutical company focused on the discovery and devel
Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering
09:25am, Tuesday, 01'st Jul 2025
FLORHAM PARK, N.J., July 01, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB) (the “Company”), a late-stage clinical biopharmaceutical company focused on the discovery and devel
Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement
08:05am, Thursday, 26'th Jun 2025
Partnership Provides Long-Term Supply of Iodine-125 and Actinium-225 Supports Advancement of Radiotherapeutic Pipeline and Plans to Initiate Phase 1b Clinical Trial of CLR-125 for Triple-Negative Brea
Good Tolerability and Robust Tumor Uptake were Observed in TNBC Animal Models Auger Emitters Offer the Potential Benefit of Enhanced Cytotoxicity, Safety and Ease-of-Use FLORHAM PARK, N.J., June 24, 2
Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split
04:30pm, Wednesday, 18'th Jun 2025
FLORHAM PARK, N.J., June 18, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (Nasdaq: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for
In Patients Receiving a Minimum of 55 mCi an Average 5.4 Months of PFS was Observed: Twice the Reported 2.25 Median In Patients Receiving a Minimum of 55 mCi an Average 5.4 Months of PFS was Observed:
Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules
09:00am, Thursday, 05'th Jun 2025
FLORHAM PARK, N.J., June 05, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery and development of drugs for
Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM)
08:05am, Wednesday, 04'th Jun 2025
Designation Supported by CLOVER WaM Phase 2 Study Data Which Reported an 83.6% Overall Response Rate (ORR) Seeking Guidance from EMA to Determine if CLOVER WaM Phase 2 Data Meets Criteria to Apply for
4 Medical Product Stocks to Watch From a Challenging Industry
12:41pm, Wednesday, 21'st May 2025
The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR reflect the favorable fu
Cellectar Biosciences Inc. (CLRB) Q1 2025 Earnings Call Transcript
02:17pm, Tuesday, 13'th May 2025
Cellectar Biosciences Inc. (NASDAQ:CLRB ) Q1 2025 Earnings Conference Call May 13, 2025 8:30 AM ET Company Participants Jim Caruso - President and CEO Chad Kolean - CFO Jarrod Longcor - COO Anne Marie
Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update
07:05am, Tuesday, 13'th May 2025
Company Seeking Conditional Approval from European Medicines Agency (EMA) for Iopofosine I 131 in Waldenstrom Macroglobulinemia based upon CLOVER WaM Phase 2 Study Data
Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025
08:05am, Wednesday, 07'th May 2025
FLORHAM PARK, N.J., May 07, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commercializa
Cellectar Announces Plan to Explore Strategic Alternatives
08:05am, Wednesday, 30'th Apr 2025
FLORHAM PARK, N.J., April 30, 2025 (GLOBE NEWSWIRE) -- Cellectar Biosciences, Inc. (NASDAQ: CLRB), a late-stage clinical biopharmaceutical company focused on the discovery, development and commerciali
4 Medical Product Stocks to Buy From a Challenging Industry
09:55am, Thursday, 17'th Apr 2025
The U.S. government's tariff imposition, especially on China, is likely to keep supply chains under pressure for the Zacks Medical Products industry. PODD, MGNX, CLRB and ALUR are likely to gain from
